Research ArticleNeuropharmacology
In Vivo Quantification of Calcitonin Gene-Related Peptide Receptor Occupancy by Telcagepant in Rhesus Monkey and Human Brain Using the Positron Emission Tomography Tracer [11C]MK-4232
Eric D. Hostetler, Aniket D. Joshi, Sandra Sanabria-Bohórquez, Hong Fan, Zhizhen Zeng, Mona Purcell, Liza Gantert, Kerry Riffel, Mangay Williams, Stacey O’Malley, Patricia Miller, Harold G. Selnick, Steven N. Gallicchio, Ian M. Bell, Christopher A. Salvatore, Stefanie A. Kane, Chi-Chung Li, Richard J. Hargreaves, Tjibbe de Groot, Guy Bormans, Anne Van Hecken, Inge Derdelinckx, Jan de Hoon, Tom Reynders, Ruben Declercq, Inge De Lepeleire, W. P. Kennedy, Rebecca Blanchard, Eugene E. Marcantonio, Cyrille Sur, Jacquelynn J. Cook, Koen Van Laere and Jeffrey L. Evelhoch
Journal of Pharmacology and Experimental Therapeutics November 2013, 347 (2) 478-486; DOI: https://doi.org/10.1124/jpet.113.206458
Eric D. Hostetler
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Aniket D. Joshi
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Sandra Sanabria-Bohórquez
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Hong Fan
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Zhizhen Zeng
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Mona Purcell
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Liza Gantert
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Kerry Riffel
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Mangay Williams
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Stacey O’Malley
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Patricia Miller
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Harold G. Selnick
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Steven N. Gallicchio
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Ian M. Bell
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Christopher A. Salvatore
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Stefanie A. Kane
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Chi-Chung Li
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Richard J. Hargreaves
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Tjibbe de Groot
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Guy Bormans
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Anne Van Hecken
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Inge Derdelinckx
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Jan de Hoon
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Tom Reynders
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Ruben Declercq
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Inge De Lepeleire
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
W. P. Kennedy
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Rebecca Blanchard
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Eugene E. Marcantonio
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Cyrille Sur
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Jacquelynn J. Cook
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Koen Van Laere
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Jeffrey L. Evelhoch
Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
Article Information
vol. 347 no. 2 478-486
PubMed
Print ISSN
Online ISSN
History
- Received May 17, 2013
- Accepted August 22, 2013
- Published online October 18, 2013.
Article Versions
- Earlier version (August 23, 2013 - 06:20).
- You are viewing the most recent version of this article.
Copyright & Usage
Copyright © 2013 by The American Society for Pharmacology and Experimental Therapeutics
Author Information
- Eric D. Hostetler,
- Aniket D. Joshi,
- Sandra Sanabria-Bohórquez,
- Hong Fan,
- Zhizhen Zeng,
- Mona Purcell,
- Liza Gantert,
- Kerry Riffel,
- Mangay Williams,
- Stacey O’Malley,
- Patricia Miller,
- Harold G. Selnick,
- Steven N. Gallicchio,
- Ian M. Bell,
- Christopher A. Salvatore,
- Stefanie A. Kane,
- Chi-Chung Li,
- Richard J. Hargreaves,
- Tjibbe de Groot,
- Guy Bormans,
- Anne Van Hecken,
- Inge Derdelinckx,
- Jan de Hoon,
- Tom Reynders,
- Ruben Declercq,
- Inge De Lepeleire,
- W. P. Kennedy,
- Rebecca Blanchard,
- Eugene E. Marcantonio,
- Cyrille Sur,
- Jacquelynn J. Cook,
- Koen Van Laere, and
- Jeffrey L. Evelhoch
- Merck Research Laboratories, West Point, Pennsylvania (E.D.H., A.D.J., S.S.-B., H.F., Z.Z., M.P., L.G., K.R., M.W., S.O., P.M. H.G.S., S.N.G., I.M.B., C.A.S., S.A.K., C.-C.L., R.J.H., C.S., J.J.C., J.L.E.); Division of Nuclear Medicine, University Hospital and KU Leuven, Leuven, Belgium (T.d.G., K.V.L.); Lab Radiopharmacy KU Leuven, Leuven, Belgium (G.B.); Merck Sharp and Dohme, Brussels, Belgium (T.R., R.D., I.D.L.); Merck Clinical Pharmacology, Upper Gwynedd, Pennsylvania (W.P.K., R.B.); Merck Clinical Pharmacology, Kenilworth, New Jersey (E.E.M.); and Center for Clinical Pharmacology, University Hospital and KU Leuven, Leuven, Belgium (A.v.H., I.D., J.d.H.)
- Address correspondence to:
Eric Hostetler, Merck Research Laboratories, WP44D-2, West Point, PA 19486. E-mail: eric_hostetler{at}merck.com
Statistics from Altmetric.com
Article usage
In this issue
Research ArticleNeuropharmacology
CGRP-R PET Occupancy by Telcagepant in Monkeys and Humans
Eric D. Hostetler, Aniket D. Joshi, Sandra Sanabria-Bohórquez, Hong Fan, Zhizhen Zeng, Mona Purcell, Liza Gantert, Kerry Riffel, Mangay Williams, Stacey O’Malley, Patricia Miller, Harold G. Selnick, Steven N. Gallicchio, Ian M. Bell, Christopher A. Salvatore, Stefanie A. Kane, Chi-Chung Li, Richard J. Hargreaves, Tjibbe de Groot, Guy Bormans, Anne Van Hecken, Inge Derdelinckx, Jan de Hoon, Tom Reynders, Ruben Declercq, Inge De Lepeleire, W. P. Kennedy, Rebecca Blanchard, Eugene E. Marcantonio, Cyrille Sur, Jacquelynn J. Cook, Koen Van Laere and Jeffrey L. Evelhoch
Journal of Pharmacology and Experimental Therapeutics November 1, 2013, 347 (2) 478-486; DOI: https://doi.org/10.1124/jpet.113.206458
Research ArticleNeuropharmacology
CGRP-R PET Occupancy by Telcagepant in Monkeys and Humans
Eric D. Hostetler, Aniket D. Joshi, Sandra Sanabria-Bohórquez, Hong Fan, Zhizhen Zeng, Mona Purcell, Liza Gantert, Kerry Riffel, Mangay Williams, Stacey O’Malley, Patricia Miller, Harold G. Selnick, Steven N. Gallicchio, Ian M. Bell, Christopher A. Salvatore, Stefanie A. Kane, Chi-Chung Li, Richard J. Hargreaves, Tjibbe de Groot, Guy Bormans, Anne Van Hecken, Inge Derdelinckx, Jan de Hoon, Tom Reynders, Ruben Declercq, Inge De Lepeleire, W. P. Kennedy, Rebecca Blanchard, Eugene E. Marcantonio, Cyrille Sur, Jacquelynn J. Cook, Koen Van Laere and Jeffrey L. Evelhoch
Journal of Pharmacology and Experimental Therapeutics November 1, 2013, 347 (2) 478-486; DOI: https://doi.org/10.1124/jpet.113.206458
Jump to section
Related Articles
Cited By...
More in this TOC Section
Similar Articles
Advertisement